Literature DB >> 16849501

PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis.

Aileen M Healy1, Elena Izmailova, Michael Fitzgerald, Russell Walker, Maureen Hattersley, Matthew Silva, Elizabeth Siebert, Jennifer Terkelsen, Dominic Picarella, Michael D Pickard, Brett LeClair, Sudeep Chandra, Bruce Jaffee.   

Abstract

T cell effector functions contribute to the pathogenesis of rheumatoid arthritis. PKC-theta transduces the signal from the TCR through activation of transcription factors NF-kappaB, AP-1, and NFAT. We examined the effects of PKC-theta deficiency on two Th1-dependent models of Ag-induced arthritis and found that PKC-theta-deficient mice develop disease, but at a significantly diminished severity compared with wild-type mice. In the methylated BSA model, cellular infiltrates and articular cartilage damage were mild in the PKC-theta-deficient mice as compared with wild-type mice. Quantitation of histopathology reveals 63 and 77% reduction in overall joint destruction in two independent experiments. In the type II collagen-induced arthritis model, we observed a significant reduction in clinical scores (p < 0.01) in three independent experiments and diminished joint pathology (p < 0.005) in PKC-theta-deficient compared with wild-type littermates. Microcomputerized tomographic imaging revealed that PKC-theta deficiency also protects from bone destruction. PKC-theta-deficient CD4(+) T cells show an impaired proliferative response, decreased intracellular levels of the cytokines IFN-gamma, IL-2, and IL-4, and significantly diminished cell surface expression of the activation markers CD25, CD69, and CD134/OX40 on memory T cells. We demonstrate decreased T-bet expression and significantly reduced IgG1 and IgG2a anti-collagen II Ab levels in PKC-theta-deficient mice. Collectively, our results demonstrate that PKC-theta deficiency results in an attenuated response to Ag-induced arthritis, which is likely mediated by the reduced T cell proliferation, Th1/Th2 cell differentiation and T cell activation before and during disease peak.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849501     DOI: 10.4049/jimmunol.177.3.1886

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.

Authors:  Myung-Ja Kwon; Ruiqing Wang; Jian Ma; Zuoming Sun
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-12       Impact factor: 2.895

2.  Structural determinants of phorbol ester binding activity of the C1a and C1b domains of protein kinase C theta.

Authors:  Agnes Czikora; Satyabrata Pany; Youngki You; Amandeep S Saini; Nancy E Lewin; Gary A Mitchell; Adelle Abramovitz; Noemi Kedei; Peter M Blumberg; Joydip Das
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-01-06       Impact factor: 3.747

3.  Protective Toxoplasma gondii-specific T-cell responses require T-cell-specific expression of protein kinase C-theta.

Authors:  Gopala Nishanth; Monika Sakowicz-Burkiewicz; Ulrike Händel; Stefanie Kliche; Xiaoqian Wang; Michael Naumann; Martina Deckert; Dirk Schlüter
Journal:  Infect Immun       Date:  2010-05-24       Impact factor: 3.441

4.  Protein kinase C-theta is required for efficient positive selection.

Authors:  Sharon Celeste Morley; K Scott Weber; Henry Kao; Paul M Allen
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 5.  The yin and yang of protein kinase C-theta (PKCθ): a novel drug target for selective immunosuppression.

Authors:  Elizabeth Yan Zhang; Kok-Fai Kong; Amnon Altman
Journal:  Adv Pharmacol       Date:  2013

6.  Protein kinase C-theta is required for development of experimental cerebral malaria.

Authors:  Mathilde Fauconnier; Marie-Laure Bourigault; Sandra Meme; Frederic Szeremeta; Jennifer Palomo; Adeline Danneels; Sabine Charron; Lizette Fick; Muazzam Jacobs; Jean-Claude Beloeil; Bernhard Ryffel; Valerie F J Quesniaux
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 7.  PKC-θ function at the immunological synapse: prospects for therapeutic targeting.

Authors:  Alexandra Zanin-Zhorov; Michael L Dustin; Bruce R Blazar
Journal:  Trends Immunol       Date:  2011-07-04       Impact factor: 16.687

Review 8.  The emerging role of protein kinase Cθ in cytoskeletal signaling.

Authors:  Izabela Michalczyk; Aleksander F Sikorski; Leszek Kotula; Richard P Junghans; Patrycja M Dubielecka
Journal:  J Leukoc Biol       Date:  2012-11-27       Impact factor: 4.962

9.  PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.

Authors:  Javier O Valenzuela; Cristina Iclozan; Mohammad S Hossain; Martin Prlic; Emily Hopewell; Crystina C Bronk; Junmei Wang; Esteban Celis; Robert W Engelman; Bruce R Blazar; Michael J Bevan; Edmund K Waller; Xue-Zhong Yu; Amer A Beg
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

10.  Prediction of PKCθ inhibitory activity using the Random Forest Algorithm.

Authors:  Ming Hao; Yan Li; Yonghua Wang; Shuwei Zhang
Journal:  Int J Mol Sci       Date:  2010-09-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.